View More Recent Stories

Apr 14, 2023 08:30AM RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida
Apr 11, 2023 08:30AM RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations
Mar 30, 2023 08:30AM RenovoRx (RNXT) Reports Positive New Data from Phase III Clinical Trial Interim Analysis
Mar 30, 2023 08:30AM  RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy
Mar 8, 2023 08:32AM RenovoRx (RNXT) Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic
Mar 8, 2023 08:30AM RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
Mar 2, 2023 08:30AM RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone
Mar 1, 2023 08:30AM RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023
Jan 25, 2023 08:30AM RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023
Jan 18, 2023 08:33AM RenovoRx (RNXT) Announces Initial Results in Pharmacokinetic Substudy
Jan 18, 2023 08:30AM RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and
Jan 5, 2023 08:34AM RenovoRx (RNXT) Strengthens Intellectual Property Portfolio with Eighth US Patent
Jan 5, 2023 08:30AM RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
Dec 15, 2022 08:30AM RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium
Nov 17, 2022 08:30AM RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers
Nov 14, 2022 08:30AM RenovoRx Reports Third Quarter 2022 Financial Results
Oct 21, 2022 08:30AM RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET
Oct 4, 2022 08:00AM RenovoRx to Participate in Upcoming October 2022 Investor Conferences
Sep 28, 2022 08:30AM RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
Sep 19, 2022 08:30AM RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
Sep 7, 2022 08:00AM RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
Aug 15, 2022 08:00AM RenovoRx Reports Second Quarter 2022 Financial Results
Jul 19, 2022 08:31AM RenovoRx (RNXT) Appoints James Ahlers as Chief Financial Officer
Jul 19, 2022 08:30AM RenovoRx Appoints James Ahlers as Chief Financial Officer
Jul 13, 2022 08:00AM RenovoRx Launches “The RenovoRx Story” Video Series
Jul 13, 2022 08:00AM RenovoRx Launches “The RenovoRx Story” Video Series
Jun 9, 2022 08:30AM RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022
Jun 2, 2022 08:30AM RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022
May 19, 2022 08:30AM RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform’s Potential Utility for the Treatment of Bile Duct Cancer
May 18, 2022 08:00AM RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
May 16, 2022 07:30AM RenovoRx Reports First Quarter 2022 Financial Results
Apr 19, 2022 08:30AM RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride Event to End Pancreatic Cancer
Mar 30, 2022 08:30AM RenovoRx Reports Full Year 2021 Financial Results
Mar 11, 2022 08:30AM RenovoRx to Participate in March 2022 Investor Conferences
Feb 22, 2022 08:00AM RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
Feb 3, 2022 09:29AM RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET
Jan 19, 2022 08:00AM RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer
Jan 6, 2022 08:00AM RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference
Nov 15, 2021 04:15PM RenovoRx Announces Third Quarter 2021 Financial Results
Nov 11, 2021 06:00AM RenovoRx Announces Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting
Nov 9, 2021 06:00AM Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer
Sep 7, 2021 06:01AM RenovoRx (RNXT) Receives 510(k) FDA Clearance for RenovoCath®
Sep 7, 2021 06:00AM RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors
View More Recent Stories